Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DR10628
- Development stage
- Phase 1
- Lead developer
- Doer Bio
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Administration
- Subcutaneous
01
Overview
DR10628 is a fatty acid-conjugated dual agonist peptide targeting the glucagon-like peptide-1 receptor (GLP-1R) and the glucose-dependent insulinotropic polypeptide receptor (GIPR). Developed by Zhejiang Doer Biologics Co., Ltd., it is designed to improve metabolic parameters by mimicking the actions of incretin hormones. The conjugation to a long-chain fatty acid is intended to extend the drug's half-life, allowing for less frequent dosing. Preclinical studies have shown significant efficacy in blood glucose reduction and weight loss. It is currently being investigated in Phase 1 clinical trials for the treatment of obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH).
02
Targets
GLP1R (GLP-1R)GIPR (Gastric inhibitory polypeptide receptor)
Beyond the preview
Go deeper on DR10628.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DR10628.